BiologicalDrug
Gastrin immunogen clinical trials
Also written G17DT.
- studies test it
- 14
- open now
- 0
- in phase 3
- 3
- first study started
- 1993
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2000 (4)
| Year | Studies |
|---|---|
| 1993 | 1 |
| 1994 | 1 |
| 1998 | 1 |
| 1999 | 3 |
| 2000 | 4 |
| 2001 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 11
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 0
Cancer Advances Inc. (14)
Studies
Open first, then newest update. How each study uses gastrin immunogen is read from its arms, and is right about nine times in ten.
Testing it · 14
- An Open Label Study to Evaluate G17DT Compared to GemcitabineCompletedPhase 3Cancer Advances Inc.NCT03200821Written as G17DT
- Two Center Study to Determine Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.CompletedPhase 2Cancer Advances Inc.NCT02223078Written as G17DT
- Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric CancerCompletedPhase 2Cancer Advances Inc.NCT02521649Written as G17DT
- Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer PatientsCompletedPhase 2Cancer Advances Inc.NCT02518529Written as G17DT
- Effect of G17DT in Patients With Stage II/III Colorectal CancerCompletedPhase 2Cancer Advances Inc.NCT02518373Written as G17DT
- Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric CancerCompletedPhase 2Cancer Advances Inc.NCT02450032Written as G17DT
- Open-label, Dose-finding Study to Determine Antibody Response to G17DT Treatment in Patients With Gastric Cancer.CompletedPhase 2Cancer Advances Inc.NCT02233712Written as G17DT
- A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal CancerTerminatedPhase 2Cancer Advances Inc.NCT02228785Written as G17DT
- Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.CompletedPhase 2Cancer Advances Inc.NCT02181465Written as G17DT
- Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal CarcinomaCompletedPhase 2Cancer Advances Inc.NCT02118064Written as G17DT-Irinotecan
- Sequential Trial of G17DT for the Treatment of Advanced Pancreatic CancerCompletedPhase 3Cancer Advances Inc.NCT02118077Written as G17DT
- Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic CarcinomaCompletedPhase 3Cancer Advances Inc.NCT00044031Written as G17DT Immunogen
- An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic CarcinomaCompletedPhase 2Cancer Advances Inc.NCT02098291Written as G17DT
- Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.CompletedPhase 2Cancer Advances Inc.NCT02098239Written as G17DT